The efficacy of alpha-lipoic acid and/or gabapentin on the oxidant-antioxidant system in patients with diabetic polyneuropathy

Hatice Ferhan Komurcu; Pervin Baran; Ozcan Erel; Omer Anlar

doi:10.18203/2320-6012.ijrms20203424

Authors

Hatice Ferhan Komurcu Department of Neurology, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey
Pervin Baran Department of Clinical Biochemistry, Ankara Şehir Hastanesi, Turkey
Ozcan Erel Department of Clinical Biochemistry, Ankara Yıldırım Beyazıt University, Turkey
Omer Anlar Department of Neurology, Ankara Yıldırım Beyazıt University, Turkey

DOI:

https://doi.org/10.18203/2320-6012.ijrms20203424

Keywords:

Alpha-lipoic acid, Diabetic polyneuropathy, Gabapentin, Paraoxonase-1, Total antioxidant status, Total oxidant status

Abstract

Background: Diabetic peripheral sensorimotor polyneuropathy is the most common complication seen in patients with diabetes mellitus (DM). Oxidant system plays a crucial role in its physiopathology. We investigated the changes in the serum levels of total antioxidant status (TAS), total oxidant status (TOS), paraoxonase-1 (PON1) and oxidative stress index (OSI) to evaluate the antioxidant efficacy of alpha lipoic acid (ALA) and/or gabapentin in patients with diabetic polyneuropathy (DPN).

Methods: Sixty-three type 2 DM patients with diabetic polyneuropathy (DPN) were enrolled in the study. Patients with DPN were divided into four groups in terms of their treatment: Group 1 consisted of treatment-naive patients; patients treated with ALA, gabapentin or combination of ALA and gabapentin comprised groups 2, 3, and 4, respectively. The patients received the medications for at least six weeks. Serum levels of TAS, TOS, PON1 and OSI were analyzed.

Results: No significant difference was observed between the groups according to the oxidative stress parameters studied.

Conclusions: The use of ALA and/or gabapentin in patients with DPN did not significantly affect the oxidative stress parameters, including TAS, TOS, PON1, and OSI.

Metrics

Metrics Loading ...

References

Tang J, Wingerchuk DM, Crum BA, Rubin DI, Demaerschalk BM. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007;13:164-7.

Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxid Med Cell Longev. 2013;2013:168039.

Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;Suppl 1:34-41.

Savas M, Yeni E, Verit A, Gulum M, Aksoy N, Ciftci H, et al. Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction. Clinics (Sao Paulo). 2010;65:1311-4.

Kuritzky L. Managing diabetic peripheral neuropathic pain in primary care. J Fam Pract. 2010;59(5 Suppl):S15-22.

McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377-85.

Uzar E, Tamam Y, Evliyaoglu O, Tuzcu A, Beyaz C, Acar A, et al. Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci. 2012;33:875-80.

Kamboj SS, Vasishta RK, Sandhir R. N-acetylcysteine inhibits hyperglycemia-induced oxidative stress and apoptosis markers in diabetic neuropathy. J Neurochem. 2010;112:77-91.

dos Santos Sales ÍM, do Nascimento KG, Feitosa CM, Saldanha GB, Feng D, de Freitas RM. Caffeic acid effects on oxidative stress in rat hippocampus after pilocarpine-induced seizures. Neurol Sci. 2011;32:375-80.

Vincet AM, Kato K, McLean LL, Soules ME, Feldman EL. Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid Redox Signal. 2009;11:425-38.

Striano P, Striano S. Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today (Barc). 2008;44:353-68.

Kale A, Börcek AÖ, Emmez H, Yildirim Z, Durdağ E, Lortlar N, et al. Neuroprotective effects of gabapentin on spinal cord ischemia-reperfusion injury in rabbits. J Neurosurg Spine. 2011;15:228-37.

Yokoyama H, Uchida H, Kuroiwa H, Kasahara J, Araki T. Role of glial cells in neurotoxin-induced animal models of Parkinson's disease. Neurol Sci. 2011;32:1-7.

Cakmak A, Soker M, Koc A, Erel O. Paraoxonase and arylesterase activity with oxidative status in children with thalassemia major. J Pediatr Hematol Oncol. 2009;31:583-7.

Aslan M, Sabuncu T, Kocyigit A, Celik H, Selek S. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2007;17:734-40.

Karsen H, Binici I, Sunnetcioglu M, Baran AI, Ceylan MR, Selek S, et al. Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B Afr Health Sci. 2012;12:114-8.

Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2006;187:74-81.

Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS. Levels of plasma malondialdehyde and erythrocyte antioxidant enzyme activities in patients with chronic hepatitis B. Hepatogastroenterology. 2003;50:766-70.

Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme. Med. Clin. (Barc). 2003;121:537-48.

Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-93.

Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet. 1983;35:1126-38.

Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud. 2009;6:230-6.

Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17:888-95.

Rutkove SB. A 52-year-old woman with disabling peripheral neuropathy: review of diabetic polyneuropathy. JAMA. 2009;302:1451-8.

Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14-36.

Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Meta Res Rev. 2006;22:257-73.

Mahdavi R, Khabbazi T, Safa J. Alpha lipoic acid supplementation improved antioxidant enzyme activities in hemodialysis patients. Int J Vitam Nutr Res. 2019;89(3-4):161-7.

Kolahi S, Mirtaheri E, Gargari BP, Khabbazi A , Hajalilou M , Asghari-Jafarabadi M, et al. Oral Administration of alpha-lipoic acid did not affect lipid peroxidation and antioxidant biomarkers in rheumatoid arthritis patients. Int J Vitam Nutr Res. 2019;89(1-2):13-21.

Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T. A comparison of Ca2+ channel blocking mode between gabapentin and verapamil: implication for protection against hypoxic injury in rat cerebrocortical slices. Br J Pharmacol. 2003;139:435-43.

Rekling JC. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett. 2003;335:167-70.

Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem. 2005;94:1131-9.

Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem. 1995;65:643-51.

de Brito TV, Júnior GJD, da Cruz Júnior JS, Silva RO, da Silva Monteiro CE, Franco AX, et al. Gabapentin attenuates intestinal inflammation: Role of PPAR-gamma receptor. Eur J Pharmacol. 2020;873:172974.